Xarelto Back On Track: J&J Answers "Complete Response" Letter And Files For Atrial Fibrillation
This article was originally published in The Pink Sheet Daily
Executive Summary
Simultaneously, partner Bayer submits applications in Europe, where rivaroxaban already is approved, for those indications and one more.